Search results
Showing 8896 to 8910 of 8922 results
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
Consultation on updated guideline to assess and prevent falls in older people
We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people.
Public consultation on our new approach to prioritising guidance now open
The consultation seeks your views about our plans to make topic selection and prioritisation more integrated, effective and timely.
The first in a new class of treatment to be recommended by NICE for treating acute migraine will soon be available on the NHS to around 13,000 people.
Avelumab not recommended as a maintenance treatment of urothelial cancer
NICE has issued draft guidance which does not recommend avelumab for maintenance treatment of urothelial cancer after platinum-based chemotherapy.
145,000 people in England to have further treatment choice for preventing migraine attacks
NICE has for the first time recommended an oral treatment for preventing migraines.
NICE recommends olaparib for early breast cancer and metastatic prostate cancer
Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
Seven technologies recommended to help people with non-specific low back pain
People with non-specific low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended in draft guidance.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use
Draft guidance for the potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).